| 0.3 0.015 (5.3%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.51 | 1-year : | 0.63 |
| Resists | First : | 0.44 | Second : | 0.54 |
| Pivot price | 0.34  |
|||
| Supports | First : | 0.28 | Second : | 0.23 |
| MAs | MA(5) : | 0.3 |
MA(20) : | 0.35 |
| MA(100) : | 0.76 |
MA(250) : | 2.85 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 4.9 |
D(3) : | 4.1 |
| RSI | RSI(14): 34.8 |
|||
| 52-week | High : | 14.22 | Low : | 0.28 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SPRC ] has closed above bottom band by 23.6%. Bollinger Bands are 45.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 23 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.32 - 0.32 | 0.32 - 0.32 |
| Low: | 0.29 - 0.29 | 0.29 - 0.29 |
| Close: | 0.3 - 0.3 | 0.3 - 0.3 |
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.
Wed, 11 Sep 2024
SciSparc stock plunges to 52-week low, hits $0.3 - Investing.com
Wed, 11 Sep 2024
SciSparc Advances $1.85 million Loan to AutoMax, Following - GlobeNewswire
Mon, 19 Aug 2024
Israel-Based Biotech Penny Stock SciSparc Outlicenses Its Cannabinoid Pain Therapy - Benzinga
Mon, 19 Aug 2024
SciSparc Ltd. Grants Exclusive License to Polyrizon - TipRanks
Fri, 16 Aug 2024
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 1.3 (%) |
| Shares Short | 35 (K) |
| Shares Short P.Month | 152 (K) |
| EPS | -14.44 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 10.77 |
| Profit Margin | -178 % |
| Operating Margin | -309.4 % |
| Return on Assets (ttm) | -33.2 % |
| Return on Equity (ttm) | -73.4 % |
| Qtrly Rev. Growth | -32.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.27 |
| EBITDA (p.s.) | -0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.02 |
| Price to Sales | 1.07 |
| Price to Cash Flow | -0.53 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|